Loading company…
TOLREMO therapeutics AG develops oral cancer therapies that target non-oncogene addiction and transcriptional escape pathways.
Founded in 2017 and headquartered in Muttenz, Switzerland, TOLREMO therapeutics AG was founded by Stefanie Flückiger-Mangual. Its lead compound, TT125-802, is an orally available small molecule inhibitor of the CBP/p300 bromodomain, being developed for solid tumors and hematological malignancies. The company raised USD 39.00 mn in a Series A round led by BioMed Partners, with participation from Pierre Fabre, in September 2023 to support a phase 1 monotherapy dose escalation study.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in